Exelixis, Inc. (NASDAQ:EXEL) Shares Purchased by Seizert Capital Partners LLC

Seizert Capital Partners LLC boosted its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 8.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 469,940 shares of the biotechnology company’s stock after buying an additional 34,875 shares during the quarter. Seizert Capital Partners LLC owned 0.16% of Exelixis worth $12,195,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of EXEL. LSV Asset Management lifted its position in shares of Exelixis by 107.7% during the 2nd quarter. LSV Asset Management now owns 5,763,728 shares of the biotechnology company’s stock worth $129,511,000 after purchasing an additional 2,989,021 shares during the last quarter. Los Angeles Capital Management LLC lifted its holdings in Exelixis by 124.0% during the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company’s stock worth $46,473,000 after buying an additional 991,494 shares during the last quarter. Swedbank AB acquired a new position in shares of Exelixis during the 1st quarter worth about $22,455,000. Farallon Capital Management LLC increased its holdings in shares of Exelixis by 1.6% in the 2nd quarter. Farallon Capital Management LLC now owns 27,102,500 shares of the biotechnology company’s stock valued at $608,993,000 after acquiring an additional 424,000 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Exelixis by 12.7% during the 2nd quarter. AQR Capital Management LLC now owns 3,281,578 shares of the biotechnology company’s stock worth $73,425,000 after acquiring an additional 370,199 shares in the last quarter. Institutional investors and hedge funds own 85.27% of the company’s stock.

Exelixis Stock Down 1.7 %

Shares of NASDAQ:EXEL opened at $34.45 on Friday. Exelixis, Inc. has a fifty-two week low of $19.20 and a fifty-two week high of $36.60. The firm’s 50-day simple moving average is $29.04 and its 200-day simple moving average is $25.15. The company has a market cap of $9.84 billion, a price-to-earnings ratio of 22.08, a PEG ratio of 0.89 and a beta of 0.51.

Exelixis (NASDAQ:EXEL) last released its earnings results on Tuesday, October 29th. The biotechnology company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.36 by $0.04. The company had revenue of $539.50 million for the quarter, compared to analysts’ expectations of $490.31 million. Exelixis had a return on equity of 20.99% and a net margin of 22.43%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.10 EPS. On average, research analysts forecast that Exelixis, Inc. will post 1.68 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Stephens upped their price target on Exelixis from $23.00 to $29.00 and gave the company an “equal weight” rating in a report on Wednesday, October 30th. Oppenheimer restated an “outperform” rating and issued a $29.00 target price on shares of Exelixis in a report on Tuesday, July 30th. Wells Fargo & Company lifted their price target on shares of Exelixis from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Guggenheim boosted their price target on shares of Exelixis from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Finally, Truist Financial lifted their target price on Exelixis from $33.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $31.44.

Insiders Place Their Bets

In other Exelixis news, EVP Dana Aftab sold 1,162 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $31.40, for a total transaction of $36,486.80. Following the transaction, the executive vice president now directly owns 498,945 shares in the company, valued at approximately $15,666,873. This represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey Hessekiel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $26.38, for a total value of $659,500.00. Following the sale, the executive vice president now directly owns 605,325 shares in the company, valued at $15,968,473.50. This trade represents a 3.97 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 248,148 shares of company stock worth $8,042,547. 2.85% of the stock is owned by corporate insiders.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.